原始出處紀錄

重大合作 / 授權交易

Lantheus 出售 CDMO 業務予 PharmaLogic,並簽署 lutetium Lu 177 dotatate 長期供應協議

Lantheus 簽署最終協議,將其 CDMO 業務及紐澤西州斯普林菲爾德廠房出售予 PharmaLogic。雙方同時同意簽署長期供應協議,由 PharmaLogic 的 Agilera 為 Lantheus 製造 lutetium Lu 177 dotatate。

關鍵事實

申報時間
2026年11月8日 下午12:00
事件
合作 / 授權交易
方向
中性
來源
SEC 8-K
可信度
有出處

來源摘錄

8-K false 0001521036 0001521036 2026-11-08 2026-11-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2026 LANTHEUS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36569 35-2318913 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 201 Burlington Road South Building Bedford , Massachusetts 01730 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (978) 671-8001 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropri

SEC 8-K

此資產的更多資訊

Lantheus 出售 CDMO 業務予 PharmaLogic,並簽署 lutetium Lu 177 dotatate 長期供應協議 | SimianX AI